Iluvien (Fluocinolone Acetonide)

Fluocinolone acetonide binds to intracellular glucocorticoid receptors in retinal cells, altering gene transcription. This suppresses production of inflammatory cytokines, stabilizes the blood‑retinal barrier, and decreases vascular permeability, thereby limiting fluid leakage into the macula and mitigating edema.

The prescribed dose of Iluvien is determined by the treating ophthalmologist. The product is supplied as a single 0.19 mg intravitreal implant that is surgically placed into the vitreous cavity, and the clinician decides whether one or multiple implants are appropriate based on the patient’s response.

Safety data for fluocinolone acetonide intravitreal implants in pregnant or nursing women are limited. Because systemic exposure is minimal, the drug is not classified as contraindicated, but the potential risks and benefits should be carefully evaluated by the prescribing physician before use in these populations.

To request Iluvien, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details—including any cold‑chain requirements—and necessary import documentation.

Iluvien provides a sustained‑release corticosteroid effect lasting up to 36 months, whereas anti‑VEGF injections require monthly or bimonthly administration. Compared with short‑acting intravitreal steroids, Iluvien reduces the frequency of repeat procedures but carries a higher cumulative risk of intraocular pressure rise and cataract formation. Choice of therapy depends on individual disease characteristics and treatment history.

Iluvien must be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. The implant should be kept in its original sealed packaging until the time of surgery, and handling should follow aseptic technique to maintain sterility.

Iluvien is implanted surgically into the vitreous cavity of the eye by a qualified retinal surgeon. The procedure involves creating a pars plana entry, inserting the 0.19 mg fluocinolone acetonide implant, and sealing the site. No repeated injections are required for the duration of drug release, which can extend up to three years.

The most serious risks include sustained elevation of intraocular pressure that may necessitate medication or surgical intervention, development of cataracts requiring extraction, endophthalmitis, and retinal detachment. Patients should be monitored regularly for these complications, and any signs of infection or vision loss should prompt immediate ophthalmic evaluation.

Iluvien is contraindicated in patients with known hypersensitivity to fluocinolone acetonide or any component of the implant, in eyes with active ocular infection or inflammation, and in individuals who have not achieved adequate control of diabetic macular edema with other approved therapies. It should also be avoided in patients where the risk of steroid‑induced intraocular pressure rise is deemed unacceptable.